• Dr.ssa Alessia Ciancio, Coordinator
• Dr. Gian Paolo Caviglia, Technician
• Dr.ssa Giulia Troshina, fellow biologist
• Dr.ssa Roberta Lasco, Doctor in training
• Dr Marco Tizzani, Doctor in training
• Dr. ssa Rosa Claudia Stasio, Doctor in training
• Dr.ssa Elisabetta Bretto, Doctor in training
• Dr.ssa Martina Marano, Doctor in training
• Dr.ssa Olivero Antonella, Technician

AOU Città della Salute e della Scienza di Torino, corso Bramante 88, padiglione Abegg groundfloor

Mail:segreteria.epatite@gmail.com

• Prof.ssa Alessia Ciancio
• Dr.ssa Antonella Olivero
• Dr. Gian Paolo Caviglia

• Prospective cohort (cross-sectional and longitudinal) of patients with viral hepatitis (HCV, HBV and HDV) associated with databases (clinical and biohumoral parameters) and biobank (blood, plasma, liver tissue from biopsy) for natural history assessment, complications and outcomes during antiviral therapy and after eradication of the virus following antiviral treatment 
• Development of networks to create linkage to care and screening projects for populations at risk for hepatic diseases with infectious aetiology, aimed at detecting the submerged and treating people with active disease 
• Clinical trials for the treatment of viral hepatitis HDV, HBV, HCV 
• Participation in the Hepatitis International Delta Network 
• Participation in international working groups for the standardization of molecular biology methods for the determination of HDV viremia 
• Development of new serological tests for the identification of the different stages of the natural history of chronic HBV infection, for the monitoring of patients in therapy with nucleos(t)idic analogues and for the prediction of occult infection in anti-HBc-positive subjects (antiHBc Igg quantitative and Hbcrag).
• Development of molecular biology methods (ddPCR) for the research of viral nucleic acids in circulation and in liver tissue.  
• Validation of HCC biomarkers (MIRRA project) 
• Participation in national working groups to draw up guidelines for antiviral treatment for hepatitis HCV, HDV and HBV

• Pubblicazioni - last 3 years - ultimi 3 anni

• Ciancio A, Ribaldone DG, Salamone R, Bruno M, Caronna S, Debernardi Venon W, Giordanino C, Mondardini A, Musso A, Pennazio M, Rolle E, Sacco M, Sprujevnik T, De Angelis C, Saracco GM. Screening and surveillance of oesophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct-acting antiviral agents. Liver Int. 2022 Feb 26. doi: 10.1111/liv.15210. Epub ahead of print. PMID: 35220668.
• Ciancio A, Ribaldone DG, Sacco M, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C. Liver Int. 2021 Mar;41(3):640. doi: 10.1111/liv.14738. Epub 2020 Dec 2. PMID: 33222363.
• Ciancio A. Impact of Direct Antiviral Agents (DAAs) on B-cell Non Hodgkin's Lymphoma in patients with chronic hepatitis C. Minerva Gastroenterol (Torino). 2021 Sep;67(3):227-233. doi: 10.23736/S2724-5985.21.02834-8. Epub 2021 Apr 15. PMID: 33856146.
• Stroffolini T, Ciancio A, Furlan C, Vinci M, Niro GA, Russello M, Colloredo G, Morisco F, Coppola N, Babudieri S, Ferrigno L, Sagnelli C, Sagnelli E; Collaborating group. Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. Eur J Clin Microbiol Infect Dis. 2021;40:607-614.
• Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol. 2014;11:68-71.

• Fellowship Program 2016 e 2018, 2022
• Clinical applications of Droplet Digital PCR for Hepatitis Delta Virus assessment in chronic hepatitis D. OLIA_RIC_LOC_15_01 
• Novel quantitative serological assays (HBcrAg and anti-HBc IgG) in the management of chronic hepatitis B infection. OLIA_RILO_17_03 
• Role of serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) to predict the therapeutic response and outcome in patients with hepatocellular carcinoma. OLIA_RILO_18_02